MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, LVTX had $22,834K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$22,834K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-7,188 -12,118
Amortization of premium on short-term investments
-1,107
Depreciation and amortization
3 115
Non-cash operating lease expense
3 139
Foreign currency exchange loss, net
-974 395
Share-based compensation expense
393 981
Accrued interest on borrowings
0 129
Gain on extinguishment of borrowings
0 5,203
Impairment of property, plant, and equipment and rou asset
40 323
Loss on the sale of property, plant, and equipment
0 -358
Prepaid expenses and other current assets
-1,300 631
Other non-current assets
-2 -85
Accounts payable
201 -1,465
Accrued expenses and other current liabilities
-1,700 -6,467
Operating lease liabilities
-3 -138
Net cash used in operating activities
-4,868 -25,394
Proceeds from sale of property and equipment
5 283
Maturities of investments
-6,924 47,000
Purchases of investments
-34,621
Net cash provided by investing activities
27,702 12,662
Net decrease in cash and cash equivalents
22,834 -12,732
Effect of exchange rate changes on cash
4,547 -
Cash and cash equivalents at beginning of period
35,015 -
Cash and cash equivalents at end of period
49,664 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

LAVA Therapeutics NV (LVTX)

LAVA Therapeutics NV (LVTX)